1819 related articles for article (PubMed ID: 30696576)
21. Bone and glucocorticoids.
Briot K
Ann Endocrinol (Paris); 2018 Jun; 79(3):115-118. PubMed ID: 29685453
[TBL] [Abstract][Full Text] [Related]
22. [Therapy of glucocorticoid induced osteoporosis].
Arazzi M; Di Fulvio G; Di Pietro LO; Grabocka X; Longo MO; Micioni G; Pezzutto A; Piscitani L; Schiazza A; Silvestri S; Vigilante G; Amoroso L; Bonomini M
G Ital Nefrol; 2017 Dec; 34(Nov-Dec):. PubMed ID: 29207221
[TBL] [Abstract][Full Text] [Related]
23. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
Anastasilakis AD; Polyzos SA; Makras P
Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
[TBL] [Abstract][Full Text] [Related]
24. The role of teriparatide in sequential and combination therapy of osteoporosis.
Meier C; Lamy O; Krieg MA; Mellinghoff HU; Felder M; Ferrari S; Rizzoli R
Swiss Med Wkly; 2014; 144():w13952. PubMed ID: 24896070
[TBL] [Abstract][Full Text] [Related]
25. Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures.
Starr J; Tay YKD; Shane E
Curr Osteoporos Rep; 2018 Aug; 16(4):519-529. PubMed ID: 29951870
[TBL] [Abstract][Full Text] [Related]
26. Postmenopausal Osteoporosis: A Clinical Review.
Watts NB
J Womens Health (Larchmt); 2018 Sep; 27(9):1093-1096. PubMed ID: 29583083
[TBL] [Abstract][Full Text] [Related]
27. Drug therapy for osteoporosis in older adults.
Reid IR; Billington EO
Lancet; 2022 Mar; 399(10329):1080-1092. PubMed ID: 35279261
[TBL] [Abstract][Full Text] [Related]
28. Medical treatment of osteoporosis.
Palacios S
Climacteric; 2022 Feb; 25(1):43-49. PubMed ID: 34382489
[TBL] [Abstract][Full Text] [Related]
29. Treatment of osteoporosis: whom, how and for how long?
Dede AD; Callan M
Br J Hosp Med (Lond); 2018 May; 79(5):259-264. PubMed ID: 29727238
[TBL] [Abstract][Full Text] [Related]
30. Osteoporosis treatment: a missed opportunity.
Milat F; Ebeling PR
Med J Aust; 2016 Aug; 205(4):185-90. PubMed ID: 27510350
[TBL] [Abstract][Full Text] [Related]
31. Osteoporosis Management.
Batur P; Rice S; Barrios P; Sikon A
J Womens Health (Larchmt); 2017 Aug; 26(8):918-921. PubMed ID: 28686517
[TBL] [Abstract][Full Text] [Related]
32. Osteoanabolic and dual action drugs.
Tabacco G; Bilezikian JP
Br J Clin Pharmacol; 2019 Jun; 85(6):1084-1094. PubMed ID: 30218587
[TBL] [Abstract][Full Text] [Related]
33. Indications to teriparatide treatment in patients with osteoporosis.
Rizzoli R; Kraenzlin M; Krieg MA; Mellinghoff HU; Lamy O; Lippuner K
Swiss Med Wkly; 2011; 141():w13297. PubMed ID: 22057669
[TBL] [Abstract][Full Text] [Related]
34. Treatment options for glucocorticoid-induced osteoporosis.
Chiodini I; Merlotti D; Falchetti A; Gennari L
Expert Opin Pharmacother; 2020 Apr; 21(6):721-732. PubMed ID: 32004105
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and Management of Osteoporosis.
Jeremiah MP; Unwin BK; Greenawald MH; Casiano VE
Am Fam Physician; 2015 Aug; 92(4):261-8. PubMed ID: 26280231
[TBL] [Abstract][Full Text] [Related]
36. Polypharmacy in Osteoporosis Treatment.
McConnell M; Shieh A
Clin Geriatr Med; 2022 Nov; 38(4):715-726. PubMed ID: 36210087
[TBL] [Abstract][Full Text] [Related]
37. Changes in bone mineral density (BMD): a longitudinal study of osteoporosis patients in the real-world setting.
Berry SD; Dufour AB; Travison TG; Zhu H; Yehoshua A; Barron R; Recknor C; Samelson EJ
Arch Osteoporos; 2018 Nov; 13(1):124. PubMed ID: 30421141
[TBL] [Abstract][Full Text] [Related]
38. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
Gallacher SJ; Dixon T
Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
[TBL] [Abstract][Full Text] [Related]
39. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture.
Hiligsmann M; Williams SA; Fitzpatrick LA; Silverman SS; Weiss R; Reginster JY
Semin Arthritis Rheum; 2019 Oct; 49(2):184-196. PubMed ID: 30737062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
